Healthcare2026-05-13| AIpedia Editorial Team

AI Medical Imaging & Radiology 2026: Aidoc vs Viz.ai vs PathAI

Compare AI medical imaging and radiology tools: Aidoc (Israel $240M, CT stroke AI standard, 1,500 US hospitals), Viz.ai (US $252M, #1 FDA-cleared LVO detection), PathAI (US $255M, pathology AI with Roche/BMS), Tempus, Annalise.ai, Cleerly, RapidAI, Paige.AI, Lunit, Qure. Features, FDA clearance, ROI. 2026 know-how for radiologists, pathologists, ER physicians.

AI medical imaging in 2026 has reached the phase of "Aidoc CT stroke AI deployed in 1,500 US hospitals / Europe / Israel, halving ER diagnosis time," "Viz.ai LVO detection cutting Door-to-Needle Time by 39 minutes," "PathAI pathology AI driving Roche/BMS drug discovery," and "Annalise.ai chest X-ray AI detecting 124 findings." Outcomes: -50% diagnosis time, -40% misses, specialist-shortage relief, 700+ US FDA clearances, $50B market by 2030 - essential medical infrastructure. Aidoc raised $240M and serves 1,500 US hospitals; Viz.ai raised $252M for #1 FDA-cleared LVO detection; PathAI raised $255M as the pathology AI standard with Roche/BMS; Tempus (NASDAQ:TEM) integrates cancer genomics + imaging; Annalise.ai detects 124 chest X-ray findings; Cleerly handles coronary CT; RapidAI processes stroke penumbra imaging. This guide covers the ten leading AI medical imaging tools.

<h2>10 Leading AI Medical Imaging Tools</h2> <ul> <li>Aidoc (Israel, $240M raised): CT stroke / pulmonary embolism / cervical fracture / brain hemorrhage AI standard, 1,500 US hospitals / Europe / Israel / Japan, 12 FDA clearances, Nvidia / General Catalyst backed, 20M cumulative cases, -50% diagnosis time.</li> <li>Viz.ai (US, $252M raised): #1 FDA-cleared LVO (large vessel occlusion) detection, Mount Sinai / Mayo Clinic adoption, -39 min Door-to-Needle Time, 5M scans, Insight Partners / Greenoaks backed.</li> <li>PathAI (US, $255M raised): pathology AI standard, Roche / BMS / Bayer partnerships for drug discovery, Harvard Medical School origin, 5,000 US pathologists, AI diagnosis + human review, Series C unicorn $1B+.</li> <li>Tempus AI (US NASDAQ:TEM, $10B mkt cap): cancer genomics + imaging + EHR integration, AI Precision Oncology, founded by Eric Lefkofsky (Groupon), 3,000 US hospitals, AI drug discovery, 2024 IPO.</li> <li>Annalise.ai (Australia, $70M raised): chest X-ray AI detecting 124 findings (industry max), US FDA clearance, Harrison.ai sister company, Royal Australian / UK NHS adoption, -40% missed diagnoses.</li> <li>Cleerly (US, $381M raised): coronary CT-Angio AI, heart attack prevention, Mayo / Cleveland Clinic adoption, Insight Partners backed, cardiology AI unicorn.</li> <li>RapidAI (US, $75M raised): stroke Penumbra / CTA / Perfusion AI, Stanford origin, 2,000 US hospitals, Viz.ai competitor, Mountain Group backed.</li> <li>Paige.AI (US, $220M raised): #1 FDA-cleared pathology AI for prostate cancer, Memorial Sloan Kettering origin, PathAI competitor, Goldman Sachs backed.</li> <li>Lunit (South Korea, KOSDAQ:328130, $4B mkt cap): chest X-ray / mammography AI, Korea / Europe / GE HealthCare partnership, KOSDAQ-listed, 10K hospitals.</li> <li>Qure.ai / Butterfly Network / iCAD (US / India / UK): Qure.ai chest X-ray AI WHO adoption, Butterfly Network (NYSE:BFLY) portable ultrasound AI, iCAD ProFound AI mammography 3,000 US sites.</li> </ul>

<h2>10 Use Cases</h2> <ul> <li>1. Stroke emergency diagnosis (Viz.ai / Aidoc / RapidAI): CT/MRI 5-min triage, FDA-cleared LVO detection, -39 min Door-to-Needle Time, 2,000 US hospitals, 800K strokes/yr saved.</li> <li>2. Pulmonary embolism / aortic dissection CT (Aidoc): ER CT 5-min triage, -40% misses, 1,500 US hospitals, Mount Sinai 30% earlier detection.</li> <li>3. Chest X-ray AI (Annalise.ai / Lunit / Qure.ai): 124 findings, TB / lung cancer / pneumonia / COVID, Royal Australian / UK NHS / WHO, -60% diagnosis time.</li> <li>4. Mammography AI breast cancer (Lunit / iCAD / Hologic): mammogram second-read, 3,000 US sites, -30% misses, -40% radiologist workload.</li> <li>5. Pathology AI (PathAI / Paige.AI): prostate / breast / colorectal cancer pathology, FDA-cleared, Roche / BMS new drugs, 5,000 US pathologists, +15% diagnostic agreement.</li> <li>6. Coronary CT AI (Cleerly / HeartFlow): heart-attack prevention, Mayo / Cleveland Clinic, AI plaque analysis, statin prescribing decisions, CMS reimbursement.</li> <li>7. Fundus AI for diabetic retinopathy (Google Health / IDx-DR): IDx-DR was the FDA's first AI clearance (2018), diabetic retinopathy, primary-care deployment, Walmart / CVS.</li> <li>8. Skin AI for skin cancer (SkinVision / Skinive / DermAssist): smartphone photo - skin cancer risk, 2M downloads, EU / Oceania medical-device clearance.</li> <li>9. Ultrasound AI (Butterfly Network / Caption Health): portable ultrasound $2K, AI guidance, ER / primary care, 100K units, J&J acquisition.</li> <li>10. Cancer genomics + imaging Precision Oncology (Tempus AI): NASDAQ:TEM, cancer genomics + imaging + EHR, AI drug discovery, 3,000 US hospitals, $10B mkt cap.</li> </ul>

<h2>ROI by Specialty</h2> <ul> <li>Radiology CT/MRI ($50K-200K/yr): Aidoc Suite $100K/yr + Viz.ai + RapidAI = $200K/yr, -50% emergency diagnosis time, -40% misses, -30% radiologist overtime, 5-15x ROI.</li> <li>Pathology AI ($100K-500K/yr): PathAI Enterprise + Paige.AI = $300K/yr, +15% diagnostic agreement, pathologist-shortage relief, +$10-100M Roche drug revenue, 50-300x ROI.</li> <li>Mammography sites ($30K-100K/yr): Lunit INSIGHT MMG + iCAD = $50K/yr, -30% misses, -40% radiologist workload, CMS reimbursement, 5-10x ROI.</li> <li>Emergency departments ($100K-300K/yr): Aidoc CT + Viz.ai LVO + RapidAI Stroke = $200K/yr, -39 min stroke Door-to-Needle, +30% survival, -50% litigation, 10-20x ROI.</li> <li>Primary care / clinics ($10K-50K/yr): IDx-DR fundus + Butterfly ultrasound + DermAssist skin = $30K/yr, early detection of diabetes / skin cancer, US CMS reimbursement, +50% referrals, 3-10x ROI.</li> </ul>

<h2>5 Risks and Mitigations</h2> <ul> <li>FDA clearance / regulatory risk: AI medical devices require FDA Class II/III clearance; uncleared AI risks malpractice / litigation / no reimbursement. Mitigation: verify FDA 510(k) clearance, CE Mark in Europe, PMDA in Japan; favor the 700+ FDA-cleared AIs (Aidoc / Viz.ai / PathAI); restrict uncleared AI to research use.</li> <li>False positives / negatives leading to medical errors: Lunit false negatives have led to missed breast cancers and lawsuits; Aidoc false positives drive unnecessary CTs; ACR / RSNA AI Bias warnings. Mitigation: use AI as a 2nd reader, with the radiologist making the final call; verify published sensitivity / specificity; compare multiple AIs (Aidoc + Lunit); re-evaluate every 3 months.</li> <li>HIPAA / GDPR patient data leakage: cloud processing of AI medical images creates HIPAA violations ($1M fines), Viz.ai 2024 breach allegations, EU AI Act 2026 high-risk for medical AI. Mitigation: sign HIPAA BAAs, verify SOC2 Type II / ISO 27001, prefer local processing (GE Healthcare Edison On-Premise), opt-in patient consent.</li> <li>Radiologist pushback / job-displacement fears: Geoffrey Hinton's 2016 "radiologists are obsolete" remark drew ACR / RSNA pushback; AI is supportive, not replacement, but salary concerns persist. Mitigation: treat AI as a co-pilot, +30% radiologist productivity, specialist-shortage relief, comply with US ACR Acceptable Use Policy and ESR European guidelines.</li> <li>Reimbursement / monetization difficulty: no US CMS reimbursement codes initially; Aidoc / Viz.ai adoption is out-of-pocket for hospitals; ROI hard to calculate; European reimbursement immature. Mitigation: track 2024 US CMS new AI reimbursement codes, Aidoc Value-Based Care, hospital ROI from reduced litigation, stroke survival improvements drive reimbursement.</li> </ul>

<h2>7 Trends for 2026</h2> <ul> <li>FDA AI/ML clearance crosses 700: in 2024 FDA passed 700+ AI/ML medical-device clearances, 60% radiology / 15% cardiovascular, accelerating pace, industry standardization.</li> <li>Foundation Models in healthcare: Google Med-PaLM 2 / Microsoft RAD-DINO / Meta DINOv2-Medical, generalist medical AI, multi-organ / multi-modality, +20% diagnostic accuracy.</li> <li>Multimodal integration (imaging + genomics + EHR): Tempus AI pioneers imaging + RNA-Seq + EHR integration for precision oncology, Bristol Myers Squibb / Roche new drugs.</li> <li>AI drug discovery (PathAI / Tempus / Recursion): pathology AI x drug development, Roche / BMS / Bayer partnerships, AlphaFold linkage, -50% drug-development time.</li> <li>EU AI Act 2026 enforcement (medical AI high-risk): medical AI classified high-risk, GDPR Art 22, CE Mark MDR strengthening, $30M fines, mandatory compliance.</li> <li>Japan market (PMDA AI clearance, reimbursement bonus): Japan PMDA AI medical-device clearances surpass 50, 2024 reimbursement bonus for AI imaging diagnostics, ELPIXEL EIRL / AI Medical Service domestic, ¥300B market by 2030.</li> <li>Generative AI radiology reports (Microsoft Rad-DINO / Google Med-PaLM 2): CT / MRI image - automated AI report, Microsoft Nuance Dragon Ambient eXperience (DAX), -50% radiologist time.</li> </ul>

AI medical imaging in 2026 differentiates by -50% diagnosis time, -40% misses, +30% survival, 700+ FDA clearances, and a $50B market by 2030. Radiology CT/MRI: Aidoc + Viz.ai + RapidAI; pathology AI: PathAI + Paige.AI; mammography: Lunit + iCAD; emergency departments: Aidoc + Viz.ai + RapidAI; primary care: IDx-DR + Butterfly + DermAssist; precision oncology: Tempus AI + PathAI. Five priorities: verify FDA 510(k) clearance, AI as 2nd reader (human final call), HIPAA BAA + SOC2, follow ACR / ESR guidelines, track CMS reimbursement codes. Roadmap: Week 1 - assess FDA-cleared AIs + vendor demos; Month 1 - pilot Aidoc / Viz.ai; Year 1 - -50% diagnosis time + +30% survival; Year 2 - Foundation Models (Med-PaLM 2 / Rad-DINO) integration; Year 3 - PMDA approval + reimbursement bonus + EU AI Act compliance fully deployed.